328 related articles for article (PubMed ID: 9787160)
1. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
3. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
4. Studies on the binding of 3H-SR121566, an inhibitor of Gp IIb-IIIa activation.
Savi P; Zamboni G; Rescanières O; Herbert JM
Thromb Haemost; 2001 Apr; 85(4):702-9. PubMed ID: 11341508
[TBL] [Abstract][Full Text] [Related]
5. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
Coller BS; Lang D; Scudder LE
Circulation; 1997 Feb; 95(4):860-7. PubMed ID: 9054743
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
[TBL] [Abstract][Full Text] [Related]
7. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport.
Nurden P; Poujol C; Durrieu-Jais C; Winckler J; Combrié R; Macchi L; Bihour C; Wagner C; Jordan R; Nurden AT
Blood; 1999 Mar; 93(5):1622-33. PubMed ID: 10029591
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
9. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic activating properties of GP IIb/IIIa blockers.
Peter K; Schwarz M; Nordt T; Bode C
Thromb Res; 2001 Sep; 103 Suppl 1():S21-7. PubMed ID: 11567665
[TBL] [Abstract][Full Text] [Related]
11. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
12. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.
Naimushin YA; Mazurov AV
Biochemistry (Mosc); 2005 Jul; 70(7):782-9. PubMed ID: 16097942
[TBL] [Abstract][Full Text] [Related]
13. The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies.
Liem TK; Teel R; Shukla S; Silver D
J Vasc Surg; 1997 Jan; 25(1):124-30. PubMed ID: 9013915
[TBL] [Abstract][Full Text] [Related]
14. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
15. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728.
Tsao PW; Forsythe MS; Mousa SA
Thromb Res; 1997 Oct; 88(2):137-46. PubMed ID: 9361367
[TBL] [Abstract][Full Text] [Related]
16. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
17. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis.
Yeh CH; Peng HC; Huang TF
Blood; 1998 Nov; 92(9):3268-76. PubMed ID: 9787163
[TBL] [Abstract][Full Text] [Related]
18. Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules.
Naimushin YA; Mazurov AV
Biochemistry (Mosc); 2003 Feb; 68(2):209-16. PubMed ID: 12693968
[TBL] [Abstract][Full Text] [Related]
19. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
[TBL] [Abstract][Full Text] [Related]
20. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
Michelson AD; Furman MI; Goldschmidt-Clermont P; Mascelli MA; Hendrix C; Coleman L; Hamlington J; Barnard MR; Kickler T; Christie DJ; Kundu S; Bray PF
Circulation; 2000 Mar; 101(9):1013-8. PubMed ID: 10704169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
